Literature DB >> 457017

[Effect of uric acid lowering drugs in low dosage in patients with hyperuricemia and hypertriglyceridemia in a randomized group study].

H R Arntz, H R Dreykluft, H Leonhardt.   

Abstract

The serum uric acid lowering effects of 100 mg Allopurinol (A), 20 mg Benzbromarone (B) and the combination of both were tested in a randomized block-trial in 12 male patients suffering from hyperuricemia and hyperlipoproteinemia type IIb/IV. Therapy periods lasted 4 weeks each. Allopurinol lowered the uric acid concentrations from 7,54 mg/100 ml to 5,95 mg/100 ml, Benzbromarone from 7,54 mg/100 ml to 6,11 mg/100 ml and the combination from 7,54 mg/100 ml to 4,90 mg/100 ml, all three significantly. The difference between the effect of the combination drug and Allopurinol and Benzbromarone respectively was also significant. An additive effect of both components is evident. Serum creatinin concentration remained constant. Uric acid and creatinin excretion could not be evaluated because of failure of patient compliance in the collecting of urine.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 457017

Source DB:  PubMed          Journal:  Fortschr Med        ISSN: 0015-8178


  5 in total

1.  Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.

Authors:  J N Colin; R Farinotti; G Fredj; M Tod; J P Clavel; E Vignon; F Dietlin
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol?

Authors:  D P Mertz; R Eichhorn
Journal:  Klin Wochenschr       Date:  1984-12-17

3.  The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout.

Authors:  F O Müller; R Schall; G Groenewoud; H K Hundt; J C van der Merwe; M van Dyk
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 4.  A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Authors:  Ming-Han H Lee; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

5.  Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study.

Authors:  Roy Fleischmann; Peter Winkle; Jesse Hall; Shakti Valdez; Sha Liu; Xiaohong Yan; Liz Hicks; Caroline Lee; Jeffrey N Miner; Michael Gillen; Martha Hernandez-Illas
Journal:  RMD Open       Date:  2018-04-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.